LEXX News and Press, Lexaria Bioscience Corp. From 12/08/23

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is planning to submit an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) in the next 45 days. The application is for the company&#x...

KELOWNA, BC / ACCESSWIRE / December 7, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Foo...

Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the ...

Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs Since 2018, human clinical studies on the technology have yielded positive results, ult...

2023-11-30 16:41:52 ET More on Lexaria Bioscience Corp. Lexaria stock rallies 20% on positive GLP-1 drug delivery study Lexaria Bioscience enters license agreement with SulfoSyn For further details see: Lexaria Bioscience files to sell 1.62M for its holders

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is reporting additional positive interim results from its human pilot study evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug s...

DehydraTECH TM -powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours; Lower blood-glucose spike after eating; and Successful first-ever D...

(TheNewswire) DehydraTECH TM -powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours; Lower blood-glucose spike a...

2023-11-27 13:24:37 ET Gainers: Redhill Biopharma Ltd. ( RDHL ) +198% . Biodexa Pharmaceuticals Plc ( BDRX ) +119% . Direct Digital Holdings ( DRCT ) +34% . Captivision ( CAPT ) +29% . MoneyHero Ltd ( MNY ) +28% . Beachbody C...

2023-11-27 12:12:40 ET More on Lexaria Bioscience Corp. Lexaria Bioscience enters license agreement with SulfoSyn Lexaria Bioscience enters into securities purchase agreement Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp. Historical earnings ...